KalVista Pharmaceuticals to present EKTERLY sebetralstat data in hereditary angioedema at AAAAI 2026

KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting

FRAMINGHAM, Mass. & SALISBURY, England–(BUSINESS WIRE)–Feb. 12, 2026– KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of three abstracts for presentation at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Philadelphia, Pennsylvania from February 27–March 2, 2026.

The following poster presentations will take place on Friday, February 27 from 2:45–3:45 pm ET in the Convention Center, Level 2, Hall E:

• Response Drivers in Sebetralstat Placebo-controlled Clinical Trials: Jonathan Bernstein, Emel Aygören-Pürsün, Danny Cohn, Henriette Farkas, William Lumry, Andrea Zanichelli, James Hao, Matthew Iverson, Michael Smith, Paul Audhya, Erik Hansen, Nathan Teuscher, Marc Riedl.
• On-demand Treatment Patterns of Hereditary Angioedema Attacks with Sebetralstat in the KONFIDENT-S Study: Marc Riedl, Emel Aygören-Pürsün, Jonathan Bernstein, Danny Cohn, William Lumry, Michael Manning, Raffi Tachdjian, Daniel Soteres, Andrea Zanichelli, James Hao, Michael Smith, Paul Audhya, Henriette Farkas.

The following investigator-initiated study late-breaking poster presentation will take place on Sunday, March 1 from 9:45–10:45 am ET in the Convention Center, Level 2, Hall E:

• Management of Attacks and Burden in Patents with Hereditary Angioedema: Results from the ECRINS Survey: Laurence Bouillet, Alexis Bocquet, Delphine Gobert, Stéphane Gayet, Sophie Debord-Peguet, Aurélie Du-Thanh, Isabelle Boccon-Gibod, Isabelle Citerne, Alexandre Belot, Olivier Fain, Magali Aubineau, Trevor Stanbury, Benoit Bouquillon, Melanie Arnaud, David Launay.

Links to all presentations will be available on the KalVista website under Publications.